Marina Biotech (MRNA) Posts Earnings Results, Misses Expectations By $0.01 EPS

Marina Biotech (OTCMKTS:MRNA) posted its earnings results on Thursday. The biotechnology company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.01), MarketWatch Earnings reports. The firm had revenue of $16.03 million during the quarter, compared to analyst estimates of $33.59 million.

MRNA stock traded up $1.66 during trading on Friday, hitting $24.92. The company had a trading volume of 535,593 shares, compared to its average volume of 968,292. Marina Biotech has a 1-year low of $13.03 and a 1-year high of $29.79.

Several equities analysts recently issued reports on MRNA shares. Piper Jaffray Companies boosted their price target on Marina Biotech from $24.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday. Zacks Investment Research cut Marina Biotech from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer restated a “buy” rating on shares of Marina Biotech in a research report on Tuesday, March 19th. Finally, Chardan Capital started coverage on Marina Biotech in a research report on Friday, April 5th. They issued a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $27.10.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2019/05/11/marina-biotech-mrna-posts-earnings-results-misses-expectations-by-0-01-eps.html.

About Marina Biotech

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Recommended Story: What is the Producer Price Index (PPI)?

Earnings History for Marina Biotech (OTCMKTS:MRNA)

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.